Scottish HTA Body OKs Vyxeos & Prevymis, But Rejects Kymriah In Lymphoma
Executive Summary
The Scottish Medicines Consortium has OKd the use of two orphan drugs, Vyxeos for AML and Prevymis for preventing CMV reactivation, but rejected Novartis’s CAR-T therapy Kymriah, for use in lymphoma.